MVIR Medivir AB (publ)

0.1106USD1.124 SEK · STO+3.12%Mkt Cap: 69.06M USDP/E: —

Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of medical treatments in areas of high unmet medical need in Sweden, the Nordic region, the rest of Europe, and internationall…

Key Statistics

Company
Market Cap69.06M USD
Enterprise Value45.03M USD
Revenue (TTM)837.24K USD
Gross Profit-3.58M USD
Net Income (TTM)-9.29M USD
Revenue/Share0.0018 USD
Last Price0.1106 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees7
CountrySE
SectorHealthcare
IndustryBiotechnology
ISINSE0020181014
Valuation
P/E (Trailing)—
P/E (Forward)-0.91
PEG0.74
EV/EBITDA-5.06
EV/Revenue53.78
P/S82.48
P/B2.42
EPS (TTM)-0.03 USD
EPS (Forward)-0.12 USD
52W Range
0.033531% of range0.2840
52W High0.2840 USD
52W Low0.0335 USD
Profitability
Gross Margin0.00%
Oper. Margin-1063.59%
EBITDA Margin0.00%
Profit Margin-1109.80%
ROE-60.82%
ROA-47.87%
ROIC-209.43%
ROCE-56.90%
Growth
Revenue Growth-20.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-7.22M USD
CapEx (TTM)—
FCF Margin-989.62%
FCF Yield-12.00%
Net Debt-24.03M USD
Net Debt/EBITDA2.70
Net Debt/FCF—
Balance Sheet
Debt/Equity0.05
Current Ratio7.79
Quick Ratio7.79
Book Value/Sh0.05 USD
Cash/Share0.04 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateMay 9, 1996
Pay Date—
Analyst Consensus
Rating0.0 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)0.3888 USD
Upside (mean)+251.4%
Target Range0.3740 USD – 0.4036 USD
0.3740+251.4% to mean0.4036
# Analysts2
Ownership
Shares Out.624.18M
Float348.53M
Insiders36.17%
Institutions15.39%
Technical
SMA 500.1490 (-25.7%)
SMA 2000.1745 (-36.6%)
Beta0.18
S&P 52W Chg12.00%
Avg Vol (30d)2.03M
Avg Vol (10d)3.29M
Technical Indicators
RSI (14)35.0
MACD-0.1150
MACD Signal-0.0944
MACD Hist.-0.0207
BB Upper0.1688 USD
BB Middle0.1327 USD
BB Lower0.0967 USD
BB Width54.34%
ATR (14)0.0111 USD
Vol Ratio (20d)1.89x

About Medivir (STO: MVIR)

›

Medivir (STO: MVIR) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 7 employees.

The shares were at 1.124 SEK on 19 November 2026, up 154.3% over 52 weeks. Its 52-week range is 0.3400 SEK to 2.885 SEK: the price is 61.0% below the high and 230.6% above the low.

Its market capitalisation is 701.58M SEK.

Medivir reports return on equity of -60.8% and revenue down 20.0% year over year.

It holds more cash than debt, a net cash position of 244.10M SEK. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 2 analysts cover the stock; their mean price target of 3.950 SEK is 251.4% above the current price. The next earnings report is expected on 18 February 2027.